[go: up one dir, main page]

GB0715939D0 - Method of treatment of duchenne muscular dystrophy - Google Patents

Method of treatment of duchenne muscular dystrophy

Info

Publication number
GB0715939D0
GB0715939D0 GBGB0715939.5A GB0715939A GB0715939D0 GB 0715939 D0 GB0715939 D0 GB 0715939D0 GB 0715939 A GB0715939 A GB 0715939A GB 0715939 D0 GB0715939 D0 GB 0715939D0
Authority
GB
United Kingdom
Prior art keywords
treatment
muscular dystrophy
duchenne muscular
duchenne
dystrophy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0715939.5A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Summit Therapeutics Ltd
Original Assignee
Vastox PLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vastox PLC filed Critical Vastox PLC
Priority to GBGB0715939.5A priority Critical patent/GB0715939D0/en
Publication of GB0715939D0 publication Critical patent/GB0715939D0/en
Priority to JP2010520500A priority patent/JP2010535831A/en
Priority to CN2008800160060A priority patent/CN102036972A/en
Priority to TW097131027A priority patent/TW200914430A/en
Priority to AU2008286326A priority patent/AU2008286326A1/en
Priority to MX2009012203A priority patent/MX2009012203A/en
Priority to PCT/EP2008/006720 priority patent/WO2009021750A2/en
Priority to CA002685605A priority patent/CA2685605A1/en
Ceased legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/06Anabolic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/10Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/12Radicals substituted by oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D263/00Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/56Benzoxazoles; Hydrogenated benzoxazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D263/57Aryl or substituted aryl radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62Benzothiazoles
    • C07D277/64Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
    • C07D277/66Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2 with aromatic rings or ring systems directly attached in position 2
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6527Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07F9/653Five-membered rings
    • C07F9/65324Five-membered rings condensed with carbocyclic rings or carbocyclic ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
GBGB0715939.5A 2007-08-15 2007-08-15 Method of treatment of duchenne muscular dystrophy Ceased GB0715939D0 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
GBGB0715939.5A GB0715939D0 (en) 2007-08-15 2007-08-15 Method of treatment of duchenne muscular dystrophy
JP2010520500A JP2010535831A (en) 2007-08-15 2008-08-14 Treatment of Duchenne muscular dystrophy
CN2008800160060A CN102036972A (en) 2007-08-15 2008-08-14 Treatment of duchenne muscular dystrophy
TW097131027A TW200914430A (en) 2007-08-15 2008-08-14 Treatment of duchenne muscular dystrophy
AU2008286326A AU2008286326A1 (en) 2007-08-15 2008-08-14 Treatment of Duchenne muscular dystrophy
MX2009012203A MX2009012203A (en) 2007-08-15 2008-08-14 Treatment of duchenne muscular dystrophy.
PCT/EP2008/006720 WO2009021750A2 (en) 2007-08-15 2008-08-14 Treatment of duchenne muscular dystrophy
CA002685605A CA2685605A1 (en) 2007-08-15 2008-08-14 Treatment of duchenne muscular dystrophy

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0715939.5A GB0715939D0 (en) 2007-08-15 2007-08-15 Method of treatment of duchenne muscular dystrophy

Publications (1)

Publication Number Publication Date
GB0715939D0 true GB0715939D0 (en) 2007-09-26

Family

ID=38566449

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0715939.5A Ceased GB0715939D0 (en) 2007-08-15 2007-08-15 Method of treatment of duchenne muscular dystrophy

Country Status (8)

Country Link
JP (1) JP2010535831A (en)
CN (1) CN102036972A (en)
AU (1) AU2008286326A1 (en)
CA (1) CA2685605A1 (en)
GB (1) GB0715939D0 (en)
MX (1) MX2009012203A (en)
TW (1) TW200914430A (en)
WO (1) WO2009021750A2 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0905667D0 (en) * 2009-04-02 2009-05-20 Summit Corp Plc Compounds for treatment of duchenne muscular dystrophy
GB0905670D0 (en) * 2009-04-02 2009-05-20 Summit Corp Plc Compounds for treatment of duchenne muscular dystrophy
WO2012080727A2 (en) * 2010-12-14 2012-06-21 Electrophoretics Limited Casein kinase 1delta (ck1delta) inhibitors
GB201217285D0 (en) * 2012-09-27 2012-11-14 Univ Central Lancashire Indole derivatives
US9246108B2 (en) * 2012-12-28 2016-01-26 Dow Global Technologies Llc Quinoline-benzoxazole derived compounds for electronic films and devices
GB201412010D0 (en) 2014-07-04 2014-08-20 Summit Corp Plc Treatment of hypertransaminasemia
WO2017168151A1 (en) * 2016-03-30 2017-10-05 Summit (Oxford) Limited Composition for the treatment of duchenne muscular dystrophy
CN116472269A (en) * 2020-09-11 2023-07-21 加利福尼亚大学董事会 Compositions and methods for treating muscular dystrophy
IL301122A (en) * 2020-09-11 2023-05-01 Univ California Preparations and methods for the treatment of muscular dystrophy
CN113264894A (en) * 2021-05-24 2021-08-17 陕西维世诺新材料有限公司 Benzoxazole derivative and preparation method thereof
US20250205247A1 (en) 2022-03-15 2025-06-26 Centre D'etude Des Cellules Souches Use of bazedoxifene for increasing muscle survival

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9815880D0 (en) * 1998-07-21 1998-09-16 Pfizer Ltd Heterocycles
GB0003256D0 (en) * 2000-02-11 2000-04-05 Darwin Discovery Ltd Heterocyclic compounds and their therapeutic use
WO2003045929A1 (en) * 2001-11-26 2003-06-05 Takeda Chemical Industries, Ltd. Bicyclic derivative, process for producing the same, and use
US6960607B2 (en) * 2001-12-13 2005-11-01 Wyeth Naphthyl benzoxazoles and benzisoxazoles as estrogenic agents
JPWO2004035522A1 (en) * 2002-08-30 2006-02-16 株式会社 ビーエフ研究所 Diagnostic probes and therapeutic agents for prion protein storage diseases and dyes for prion protein
JP2006513159A (en) * 2002-11-01 2006-04-20 メルク エンド カムパニー インコーポレーテッド Carbonylamino-benzimidazole derivatives as androgen receptor modulators
EP1454627A1 (en) * 2003-03-06 2004-09-08 MyoContract Ltd. Alpha-Keto carbonyl calpain inhibitors
EP1986633B1 (en) * 2006-02-10 2014-07-30 Summit Corporation Plc Treatment of duchenne muscular dystrophy

Also Published As

Publication number Publication date
JP2010535831A (en) 2010-11-25
MX2009012203A (en) 2009-12-18
WO2009021750A3 (en) 2014-02-20
CN102036972A (en) 2011-04-27
AU2008286326A1 (en) 2009-02-19
TW200914430A (en) 2009-04-01
CA2685605A1 (en) 2009-02-19
WO2009021750A2 (en) 2009-02-19

Similar Documents

Publication Publication Date Title
GB0715938D0 (en) Method of treatment of duchenne muscular dystrophy
IL228598A0 (en) Treatment of duchenne muscular dystrophy
GB0821307D0 (en) Compounds for treatment of duchenne muscular dystrophy
GB0815369D0 (en) Compounds for treatment of duchenne muscular dystrophy
IL193314A0 (en) Treatment of duchenne muscular dystrophy
GB0822981D0 (en) Compounds for treatment of duchenne muscular dystrophy
ZA200806630B (en) Method of treatment for muscular dystrophy
GB0715939D0 (en) Method of treatment of duchenne muscular dystrophy
RS55735B1 (en) Drug combinations for the treatment of duchenne muscular dystrophy
GB0715087D0 (en) Drug combinations for the treatment of duchenne muscular dystrophy
ZA200806986B (en) Treatment of duchenne muscular dystrophy
EP2350641A4 (en) Method of treatment
GB0715937D0 (en) Method of treatment og duchenne muscular dystrophy
PL2576582T3 (en) Treatment of muscular dystrophy
PL2318573T3 (en) Anti-corrosion treatment method
GB0905664D0 (en) Compounds for treatment of duchenne muscular dystrophy
GB0809314D0 (en) Compounds for treating muscular dystrophy
GB0905670D0 (en) Compounds for treatment of duchenne muscular dystrophy
GB0602767D0 (en) Treatment of muscular dystrophy
GB0614690D0 (en) Method of treatment of duchenne muscular dystrophy
GB0905667D0 (en) Compounds for treatment of duchenne muscular dystrophy
GB0619282D0 (en) Treatment of duchenne muscular dystrophy
GB0619281D0 (en) Treatment of duchenne muscular dystrophy
GB0617737D0 (en) Treatment of duchenne muscular dystrophy
GB0617739D0 (en) Treatment of duchenne muscular dystrophy

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)